Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (10685)	7/8/1999 5:45:00 PM
From: Arthur Radley	Read Replies (3) \| Respond to of 17367

George, Will the Alergen payment also hit in the upcoming release? One site I looked at showed XOMA breaking even for the Q, so I agree that earnings of this type isn't what we are looking for.....product revenue is the magic wand.

To: aknahow who wrote (10685)	7/8/1999 10:23:00 PM
From: Biomaven	Read Replies (2) \| Respond to of 17367

George, I have not posted this before since the chances were dependent upon the last floorless convertible being actually bought at the 60% premium figure. It now looks like it has a chance of being issued at that price. The premium over market for the shares sold will come onto XOMA's books as "income". Do you have a ready link to the terms of this deal? I would think they would only book income if the company was selling common at a premium, not another instrument convertible at a premium to the market. So is Xoma up because its up? (My weak attempt at a Yogi Berrism <g>). In other words is it up because something good has happened that has somehow leaked (not necessarily from the company, of course), or because people are assuming that something good has happened because its up ... (I'm assuming the psoriasis results were not enough to inspire the recent surge.) Congrats to all you hardy longs, BTW. I chickened out a long time back. Peter